MedTrace Logo

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

NCT05601752 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-02-25

No results posted yet for this study

Summary

This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.

Conditions

Interventions

GENETIC

Autologous genetically modified ADP-A2M4CD8 cells

Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1

COMBINATION_PRODUCT

Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab

Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks

Sponsors & Collaborators

  • GOG Foundation

    collaborator NETWORK

  • USWM CT, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-26
Primary Completion
2026-08-12
Completion
2026-08-12
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05601752 on ClinicalTrials.gov